Avinger Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Avinger yıllık ortalama 5.3% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 12% annual. Gelirler azalıyor .

Anahtar bilgiler

5.3%

Kazanç büyüme oranı

77.1%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	8.9%
Gelir büyüme oranı	-4.4%
Özkaynak getirisi	-480.2%
Net Marj	-239.0%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Avinger nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:AVGR Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	7	-17	15	4
30 Jun 24	7	-15	15	4
31 Mar 24	8	-16	15	4
31 Dec 23	8	-18	14	5
30 Sep 23	8	-19	14	5
30 Jun 23	8	-22	14	5
31 Mar 23	8	-22	14	5
31 Dec 22	8	-27	14	4
30 Sep 22	9	-28	15	5
30 Jun 22	9	-29	15	5
31 Mar 22	9	-27	16	5
31 Dec 21	10	-22	16	6
30 Sep 21	10	-21	16	6
30 Jun 21	10	-21	15	6
31 Mar 21	9	-22	14	6
31 Dec 20	9	-23	14	6
30 Sep 20	9	-23	15	6
30 Jun 20	9	-23	15	6
31 Mar 20	10	-24	17	6
31 Dec 19	9	-23	17	6
30 Sep 19	9	-24	17	6
30 Jun 19	8	-25	18	6
31 Mar 19	8	-26	18	6
31 Dec 18	8	-36	18	6
30 Sep 18	8	-39	18	6
30 Jun 18	8	-43	19	7
31 Mar 18	8	-49	20	9
31 Dec 17	10	-49	25	11
30 Sep 17	13	-52	29	13
30 Jun 17	16	-55	34	15
31 Mar 17	18	-55	37	15
31 Dec 16	19	-56	40	16
30 Sep 16	17	-56	40	15
30 Jun 16	15	-56	38	16
31 Mar 16	13	-53	35	16
31 Dec 15	11	-50	29	16
30 Sep 15	11	-44	25	15
30 Jun 15	11	-40	23	13
31 Mar 15	11	-37	21	12
31 Dec 14	11	-32	19	11
30 Sep 14	12	-32	18	12
30 Jun 14	12	-33	20	12
31 Mar 14	12	-37	23	14
31 Dec 13	13	-40	26	16

Kaliteli Kazançlar: AVGR şu anda kârlı değil.

Büyüyen Kar Marjı: AVGR şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AVGR kârlı değildir, ancak son 5 yılda zararlarını yılda 5.3% oranında azaltmıştır.

Büyüme Hızlandırma: AVGR 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: AVGR kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 10.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: AVGR hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -480.23% ) sahiptir.

Avinger Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Recent updates

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Insufficient new directors

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Consensus EPS estimates upgraded to US$3.59 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avinger GAAP EPS of -$0.94 beats by $0.15, revenue of $2.13M misses by $0.25M

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Consensus forecasts updated

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Is Avinger (NASDAQ:AVGR) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

Is Avinger (NASDAQ:AVGR) A Risky Investment?

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Avinger shares fall after Q1 results fail to impress Wall Street

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Avinger Regains Compliance with Nasdaq Listing Requirements

Does Avinger (NASDAQ:AVGR) Have A Healthy Balance Sheet?

New 90-day high: US$0.89

Avinger 'Hot Penny Stock to buy' - Robinhood

New 90-day high: US$0.35

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Third quarter 2020 earnings released: US$0.079 loss per share

Revenue beats expectations, earnings disappoint

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$0.29

New 90-day low: US$0.29

Analysts increase EPS estimates to -US$0.69

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

New 90-day high - US$0.67

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi